Core Viewpoint - Walgreens is nearing a $10 billion deal to go private, which has resulted in an increase in its stock price [1] Group 1: Company Overview - The potential deal indicates a significant shift in Walgreens' strategy, moving towards privatization [1] - The stock price of Walgreens has risen in response to the news of the impending deal [1] Group 2: Financial Implications - The deal is valued at approximately $10 billion, highlighting the scale of the transaction [1] - The privatization could lead to changes in operational focus and financial restructuring for Walgreens [1]

Group 1 - Walgreens Boots Alliance Inc. is nearing a $10 billion deal to sell itself to Sycamore Partners, a private-equity firm [1] - The deal would result in Walgreens being taken private and likely broken up [1] - The potential announcement of the deal could occur as soon as Thursday [1]

Group 1: Logitech International SA (LOGI) - LOGI shares are down 2.9%, trading at $98.24, following a downgrade to "underperform" from "neutral" by BofA Global Research due to recent struggles and tariff threats [1][2] - The stock recently attempted to break its three-year high of $105.65 but closed below its 20-day moving average for the first time since January, despite an 18.8% increase so far in 2025 [2] - Options traders are showing bullish sentiment with a 50-day call/put volume ratio of 31.05, which is higher than 98% of annual readings [3] Group 2: Walgreens Boots Alliance Inc (WBA) - WBA shares are down 3.8%, trading at $10.81, following a downgrade to "sell" from "hold" by Deutsche Bank due to high uncertainty, and the stock has a year-over-year deficit of 49.7% [1][3] - Despite a 15.5% year-to-date gain, WBA has faced overhead pressure at the $12 level, capping rallies since late January [3] - Options activity is notably bullish, with 28,000 calls traded, which is double the intraday average volume, compared to only 5,051 puts [4]

Company Performance - Walgreens Boots Alliance (WBA) ended the recent trading session at $11.23, showing a +1.72% increase from the previous day's closing price, outperforming the S&P 500 which fell by 1.59% [1] - Over the past month, WBA shares have decreased by 1.87%, underperforming the Retail-Wholesale sector's gain of 0.87% and the S&P 500's loss of 2.23% [2] Upcoming Earnings - The upcoming earnings release is highly anticipated, with projected EPS at $0.53, indicating a significant 55.83% decline compared to the same quarter last year. Revenue is expected to reach $38.07 billion, reflecting a 2.75% increase year-over-year [3] - For the full year, analysts expect earnings of $1.60 per share and revenue of $151.57 billion, representing changes of -44.44% and +2.65% respectively from the previous year [4] Analyst Estimates - Recent changes to analyst estimates suggest a positive outlook for WBA, with upward revisions indicating confidence in the company's performance and profit potential [5] - The Zacks Rank system, which assesses estimate changes, currently ranks WBA at 2 (Buy), with a 0.76% upward shift in the consensus EPS estimate over the past month [7] Valuation Metrics - WBA has a Forward P/E ratio of 6.9, which is higher than the industry average Forward P/E of 5.93, indicating a premium valuation [8] - The company has a PEG ratio of 1.38, compared to the industry average PEG ratio of 0.83, suggesting that WBA's valuation considers its expected earnings growth [9] Industry Context - The Retail - Pharmacies and Drug Stores industry, part of the Retail-Wholesale sector, holds a Zacks Industry Rank of 3, placing it in the top 2% of over 250 industries, indicating strong performance potential [10]

Core Viewpoint - Walgreens Boots Alliance shares experienced a notable increase due to news of a potential buyout by Sycamore Partners, despite broader market declines [1][3]. Group 1: Buyout Proposal - Sycamore Partners is proposing to split Walgreens into three separate entities: the main Walgreens pharmacy in the U.S., Boots pharmacy in the U.K., and specialty pharmaceutical unit Shields Health Solutions [2]. - Sycamore Partners appears to have secured the necessary financing for the proposed buyout [2]. Group 2: Market Reaction - Walgreens shares rose by as much as 7.3% before settling at a 2.2% gain, indicating a positive market reaction to the buyout rumors [1]. - Previous rumors of a buyout in December led to a spike in shares, but they retreated due to market volatility and lack of follow-through [3]. Group 3: Investment Considerations - Investors are cautioned against buying solely based on the potential buyout, as talks may not materialize [4]. - It is suggested that investors should consider the stabilization of Walgreens' earnings and the effectiveness of the turnaround plan under new CEO Tim Wentworth, who took over in late 2023 [4].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Walgreens Boots Alliance, Inc. common stock between April 2, 2020, and January 16, 2025, of the March 31, 2025, lead plaintiff deadline for a class action lawsuit [1] Group 1: Class Action Details - Investors who bought Walgreens common stock during the specified Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2] - A class action lawsuit has already been filed, and interested parties can join by contacting Rosen Law Firm [3][6] - The lead plaintiff must file a motion with the Court by March 31, 2025, to represent other class members in the litigation [3] Group 2: Law Firm Credentials - Rosen Law Firm emphasizes the importance of selecting qualified counsel with a successful track record in securities class actions, highlighting its own achievements in this area [4] - The firm has secured significant settlements for investors, including over $438 million in 2019 and has been ranked highly in securities class action settlements since 2013 [4] Group 3: Case Allegations - The lawsuit alleges that Walgreens failed to disclose widespread violations of federal law regarding prescription medication dispensation and reimbursement during the Class Period [5] - It is claimed that Walgreens' conduct posed a risk of regulatory scrutiny, civil liability, and reputational harm, and that its revenue from prescription sales was unsustainable due to unlawful practices [5] - The lawsuit asserts that Walgreens' public statements were materially false and misleading, leading to investor damages when the truth was revealed [5]

Core Viewpoint - Walgreens Boots Alliance, Inc. is facing a class action lawsuit for alleged violations of the Securities Exchange Act of 1934, with claims of misleading statements and unlawful conduct regarding prescription medication dispensing [1][3][4] Summary by Sections Class Action Lawsuit Details - The class action lawsuit is titled Klein v. Walgreens Boots Alliance, Inc., and covers stock purchases made between April 2, 2020, and January 16, 2025 [1] - Investors have until March 31, 2025, to seek appointment as lead plaintiff in the lawsuit [1] Allegations Against Walgreens - The lawsuit alleges that Walgreens made false statements and failed to disclose ongoing violations of federal laws related to prescription medication [3] - Specific allegations include the dispensing of unlawful prescriptions and seeking reimbursement from federal health care programs, which led to a significant drop in stock price following the announcement of a civil complaint by the U.S. Department of Justice [4] Impact on Stock Price - Following the DOJ's announcement on January 17, 2025, Walgreens' stock price fell by more than 12% over two trading sessions [4] Lead Plaintiff Process - The Private Securities Litigation Reform Act of 1995 allows any investor who purchased Walgreens stock during the class period to seek lead plaintiff status, which involves directing the lawsuit on behalf of all class members [5] About Robbins Geller - Robbins Geller Rudman & Dowd LLP is a leading law firm in securities fraud cases, having recovered $6.6 billion for investors in class action cases, significantly more than any other firm in the last four years [6]

Core Insights - Grubhub has partnered with Walgreens to offer on-demand delivery of 15,000 everyday essential items from Walgreens and Duane Reade locations nationwide [1][2][3] - The collaboration aims to enhance customer experience by broadening access to convenience items, with data indicating that customers who shop from convenience merchants on Grubhub order nearly three times more per month than those who do not [2][3] - Walgreens and Duane Reade are now part of Grubhub+, Grubhub's loyalty program, providing members with benefits such as $0 delivery fees and exclusive offers [3][7] Company Overview - Grubhub is a leading U.S. ordering and delivery marketplace, connecting customers with local restaurants and convenience retailers, featuring 375,000 merchants across over 4,000 U.S. cities [4] - Walgreens, founded in 1901, serves nearly 9 million customers daily through approximately 8,500 stores in the U.S. and Puerto Rico, employing around 220,000 team members [5][6] - Walgreens is part of Walgreens Boots Alliance, Inc., which integrates healthcare, pharmacy, and retail services, with pharmacists playing a crucial role in patient care [6]

Core Viewpoint - Walgreens Boots Alliance, Inc. is facing allegations of issuing materially false and misleading statements regarding its compliance with federal laws governing prescription medication dispensation and reimbursement during the class period from April 2, 2020, to January 16, 2025 [1] Group 1: Allegations and Legal Context - The complaint alleges that Walgreens continued to engage in widespread violations of federal law despite its claims of improved regulatory compliance [1] - The conduct of Walgreens is said to expose the company to increased risks of regulatory scrutiny, civil liability, and reputational harm [1] - Revenues from the sale of prescription medications are claimed to be unsustainable due to their derivation from unlawful conduct [1] Group 2: Shareholder Information - Shareholders who purchased shares of WBA during the specified class period are encouraged to register for potential lead plaintiff appointment, with a deadline set for March 31, 2025 [2] - Registered shareholders will be enrolled in a portfolio monitoring software to receive updates throughout the lifecycle of the case [2] Group 3: Law Firm Background - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting the rights of investors affected by deceit, fraud, and illegal business practices [3] - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors who suffered losses due to misleading statements or omissions [3]

Core Viewpoint - A class action lawsuit has been filed against Walgreens Boots Alliance, Inc. for allegedly misleading investors regarding its distribution of opioid prescriptions and failing to comply with federal regulations [1][2]. Allegations - The lawsuit claims that Walgreens engaged in widespread violations of federal law concerning prescription medication dispensation and reimbursement, despite its stated commitment to regulatory compliance [2]. - It is alleged that Walgreens' revenues from prescription medications were unsustainable due to unlawful conduct, which could lead to increased regulatory scrutiny and civil liability [2]. DOJ Complaint - On January 17, 2025, the Department of Justice (DOJ) filed a civil complaint against Walgreens, alleging that the company knowingly filled millions of illegitimate prescriptions for controlled substances, including excessive quantities of opioids [3]. - The complaint states that Walgreens was aware of its responsibility to maintain compliance and that its business practices contradicted previous commitments to uphold regulatory measures [3]. - Following the DOJ's announcement, Walgreens' stock price dropped by $1.56 per share, a decline of 12.06%, closing at $11.37 per share on January 21, 2025 [3]. Class Action Participation - Shareholders of Walgreens Boots Alliance, Inc. may be eligible to participate in the class action lawsuit, with options to serve as lead plaintiff or remain an absent class member [4].